177Lu Dotatate vs Sequential 177Lu Dotatate and 90Y Dotatate: Treatment Outcomes for PRRT Patients at the Christie - A Clinical Audit

#1098

Introduction: The traditional treatment regime of somatostatin receptor positive NETs by molecular radiotherapy was based on single radionuclides (e.g. 90Y Dotatate or 177Lu Dotatate), delivered as multiple cycles to allow normal tissue recovery. However a newer practice of alternating tcycles of 177Lu and Y90 Dotatate was implemented at the Christie following introduction of this regime in some European centres. Subsequent follow up studies have indicated that longer overall survival and reduced loss of kidney function is found in patient cohorts treated with combined 177Lu and 90Y regimes to either 177Lu or 90Y alone.

Aim(s): An audit was conducted at our centre of patient responses to PRRT to determine whether the combined radionuclide regime was delivering equivalent outcomes to the all Lutetium regime given to the earlier patients, without any additional toxicities.

Materials and methods: Comparisons were made of haematological toxicity, renal toxicity and other side effect such as nausea, lethargy, diarrhoea, carcinoid symptoms. Also red marrow dose was estimated from blood samples for all patients and related to blood count response.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Tipping J

Authors: Page E, Tipping J, Birch E, Hamilton D, Manoharan P,

Keywords: PRRT, Toxicity, Audit, RM Dose,